Suppr超能文献

小鼠 GPAT1 缺乏以模型依赖的方式调节 NASH 进展。

GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner.

机构信息

WRDM Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts.

WRDM Drug Safety, Research and Development, Pfizer Inc, Groton, Connecticut.

出版信息

Cell Mol Gastroenterol Hepatol. 2024;17(2):279-291. doi: 10.1016/j.jcmgh.2023.10.002. Epub 2023 Oct 14.

Abstract

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD), and its more severe form, nonalcoholic steatohepatitis (NASH), is the leading cause for liver failure and liver cancer. Although the etiology is likely multifactorial, genes involved in regulating lipid metabolism are enriched in human NAFLD genome-wide association studies (GWAS), pointing to dysregulated lipid metabolism as a major pathogenic factor. Glycerol-3-phosphate acyltransferase 1 (GPAT1), encoded by GPAM, converts acyl-CoAs and glycerol-3-phosphate into lysophosphatidic acid and has been shown to regulate lipid accumulation in the liver. However, its role in mediating the progression from NAFLD to NASH has not been explored.

METHODS

GPAT1-deficient mice were generated and challenged with diets inducing hepatic steatosis and NASH. Effects of GPAT1 deficiency on lipid and systemic metabolic end points were evaluated.

RESULTS

Ablating GPAT1 globally or specifically in mouse hepatocytes reduced hepatic steatosis in the context of diet-induced or genetic obesity. Interestingly, blunting of progression from NAFLD to NASH in global GPAT1 knockout (KO) mice was model dependent. GPAT1 KO mice were protected from choline deficient, amino acid defined high-fat diet-induced NASH development, but not from the high fat, high carbohydrate, and high cholesterol diet-induced NASH.

CONCLUSIONS

Our preclinical data support the notion that lipid metabolism pathways regulated by GPAT1 in hepatocytes play an essential role in NASH progression, albeit in a model-dependent manner.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)及其更严重的形式,即非酒精性脂肪性肝炎(NASH),是导致肝衰竭和肝癌的主要原因。尽管其病因可能是多因素的,但参与调节脂质代谢的基因在人类非酒精性脂肪性肝病全基因组关联研究(GWAS)中丰富,表明脂质代谢失调是主要的致病因素。甘油-3-磷酸酰基转移酶 1(GPAT1)由 GPAM 编码,将酰基辅酶 A 和甘油-3-磷酸转化为溶血磷脂酸,并已被证明可调节肝脏中的脂质积累。然而,其在介导从 NAFLD 向 NASH 进展中的作用尚未得到探索。

方法

生成了 GPAT1 缺陷型小鼠,并对其进行了诱导肝脂肪变性和 NASH 的饮食挑战。评估了 GPAT1 缺失对脂质和全身代谢终点的影响。

结果

全身性或特异性敲除 GPAT1 可减少饮食诱导或遗传肥胖小鼠的肝脂肪变性。有趣的是,全身性 GPAT1 敲除(KO)小鼠从 NAFLD 向 NASH 进展的减缓取决于模型。胆碱缺乏型、氨基酸定义型高脂肪饮食诱导的 NASH 发展中,GPAT1 KO 小鼠得到了保护,但在高脂肪、高碳水化合物和高胆固醇饮食诱导的 NASH 中则没有。

结论

我们的临床前数据支持这样的观点,即肝细胞中由 GPAT1 调节的脂质代谢途径在 NASH 进展中起着至关重要的作用,尽管在模型依赖性方面有所不同。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59fd/10829521/52ee7bf0320a/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验